UCL Cancer Institute



FOXFIRE combined analysis study results announced

Analysis from the FOXFIRE studies, led by Professor Ricky Sharma, indicates no benefit in overall survival from adding selective internal radiotherapy [SIRT] to first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer.

Publication date:

Drug improves survival of patients with rare cancer by almost a quarter

Patients who take the chemotherapy drug, capecitabine, after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug, according to the results of a phase III clinical trial presented at the 2017 ASCO Annual Meeting in Chicago.

Publication date:

Tracking unstable chromosomes helps predict lung cancer’s return

Scientists at UCL, UCLH and the Francis Crick Institute have found that unstable chromosomes within lung tumours increase the risk of cancer returning after surgery, and have used this new knowledge to detect relapse long before standard testing.

Publication date:

International team receive $1.2 million boost for neuroendocrine cancer research

A scientific collaboration between UCL, Dana-Farber Cancer Institute, UCSF Medical Centre and the UCL Cancer Institute / Royal Free Hospital London has been awarded a $1.2m accelerator grant from the Neuroendocrine Tumor Research Foundation (NETRF) to help advance research into small intestine neuroendocrine tumours (SI-NETs).

Publication date: